Literature DB >> 10524890

The significance of prior benign needle biopsies in men subsequently diagnosed with prostate cancer.

J I Epstein1, P C Walsh, G Akingba, H B Carter.   

Abstract

PURPOSE: We determine the relationship between a history of benign needle biopsies, and the volume and location of cancer.
MATERIALS AND METHODS: We evaluated 395 men who underwent radical prostatectomy for stage T1c (nonpalpable) prostate cancer.
RESULTS: Of the men 74 had 1 or more prior benign needle biopsies. Prior benign biopsy correlated with tumor in the anterior or lateral portion of the radical prostatectomy specimen (p = 0.044) and prostate weight (p = 0.002). The likelihood of prior benign biopsy was 32.5% for men with a 75 gm. or greater prostate compared to 15.2% for those with a less than 75 gm. prostate. Although prior benign biopsy correlated with "very limited" tumor in the prostate (less than 0.2 cc, no Gleason pattern 4 or 5 and organ confined disease) (p = 0.005), only 28.4% of patients with prior benign biopsy had "very limited" tumor. In a multivariate analysis prior benign biopsy correlated only with anterior or lateral distribution and enlarged prostate size. Of the prior benign biopsy cases 12% had positive margins, average tumor volume was 1.15 cc and 27% had nonorgan confined disease. These figures were not different from those in cases with cancer on the first biopsy. In prior benign biopsy cases although PSA velocity predicted tumor volume and "very limited" tumor, a specific clinically useful cutoff value was not present. Needle biopsy grade and number of positive cores were not predictive of tumor volume or "very limited" cancer.
CONCLUSIONS: Prior benign biopsy in men subsequently diagnosed with prostate cancer does not indicate indolent tumor. Benign biopsies are more likely in larger prostate glands and when cancer is in the anterior and lateral regions of the gland, suggesting the need for different biopsy strategies to improve cancer detection.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10524890

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  7 in total

1.  Detection rate of clinically insignificant prostate cancer increases with repeat prostate biopsies.

Authors:  Bumsoo Park; Seong-Soo Jeon; Sung-Ho Ju; Byong-Chang Jeong; Seong-Il Seo; Hyun-Moo Lee; Han-Yong Choi
Journal:  Asian J Androl       Date:  2012-12-31       Impact factor: 3.285

Review 2.  The current and potential role of cryoablation as a primary therapy for localized prostate cancer.

Authors:  Aaron E Katz; John C Rewcastle
Journal:  Curr Oncol Rep       Date:  2003-05       Impact factor: 5.075

3.  Are repeat prostate biopsies safe? A cohort analysis from the SEARCH database.

Authors:  Ryan P Kopp; Sean P Stroup; Florian R Schroeck; Stephen J Freedland; Frederick Millard; Martha K Terris; William J Aronson; Joseph C Presti; Christopher L Amling; Christopher J Kane
Journal:  J Urol       Date:  2012-04-11       Impact factor: 7.450

4.  Prostate cancer diagnosed after repeat biopsies have a favorable pathological outcome but similar recurrence rate.

Authors:  Ernesto Lopez-Corona; Makoto Ohori; Thomas M Wheeler; Victor E Reuter; Peter T Scardino; Michael W Kattan; James A Eastham
Journal:  J Urol       Date:  2006-03       Impact factor: 7.450

5.  Are more low-risk prostate cancers detected by repeated biopsy? A retrospective pilot study.

Authors:  Seung Je Lee; Insang Hwang; Eu Chang Hwang; Seung Il Jung; Taek Won Kang; Dong Deuk Kwon; Kwangsung Park
Journal:  Korean J Urol       Date:  2013-06-12

6.  Differences in Postoperative Pathological Outcomes between Prostate Cancers Diagnosed at Initial and Repeat Biopsy.

Authors:  In Ho Khang; Yun Beom Kim; Seung Ok Yang; Jeong Ki Lee; Tae Young Jung
Journal:  Korean J Urol       Date:  2012-08-16

Review 7.  Focal or subtotal therapy for early stage prostate cancer.

Authors:  J Stephen Jones
Journal:  Curr Treat Options Oncol       Date:  2007-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.